ロード中...
Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016
In January 2013, a novel vaccine against Neisseria meningitidis serogroup B, the multicomponent meningococcal serogroup B vaccine (4CMenB), was approved by the European Medicines Agency. We aimed to evaluate the safety profile of this vaccine. Methods: All adverse events following immunisation (AEFI...
保存先:
| 出版年: | Euro Surveill |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
European Centre for Disease Prevention and Control (ECDC)
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5930728/ https://ncbi.nlm.nih.gov/pubmed/29717697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2807/1560-7917.ES.2018.23.17.17-00468 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|